Quick answer: Lawful online tirzepatide starts with a licensed prescriber and ends at a pharmacy licensed by your state. FDA has approved the ingredient as the brand drugs Zepbound and Mounjaro, both carrying a boxed warning. Compounded tirzepatide is not FDA-approved, and FDA says it does not review compounded drugs for safety, effectiveness or quality before they are marketed. FDA also warns about products labeled "for research purposes."
This page separates two products that share a name: the brand drugs and the compounded versions. It states what FDA has said, with dates. Some links on this page are affiliate links, and we may earn a commission if you use them. We do not rank the two routes against each other, and we say where a fact could not be confirmed.
- FDA status
Zepbound and Mounjaro are FDA-approved brand drugs. Compounded tirzepatide is not FDA-approved.
- Lawful route
A licensed prescriber writes the prescription, and a pharmacy licensed by your state fills it
- Brand or compounded
Both exist. The brand drugs are made by Lilly; compounded versions are made by 503A pharmacies or 503B outsourcing facilities.
- Whoosh offers this
Yes, in compounded form, per Whoosh's own pages (read 2026-10-07)
As of 2026-10-07; the sources sit at the foot of the page.
Brand drug vs compounded copy
Both products contain the same named ingredient. That is where the similarity ends, and FDA is specific about it. FDA's page for telehealth companies, current as of 2026-06-15, reminds them not to describe a compounded drug as generic or as "the same as a drug approved by FDA." On 2026-03-03 FDA announced 30 warning letters to telehealth companies over misleading claims about compounded GLP-1 drugs, including claims that implied sameness with approved products.
| Brand: Zepbound, Mounjaro | Compounded tirzepatide | |
|---|---|---|
| FDA approval | Approved | Not FDA-approved |
| What FDA reviews | Safety, effectiveness and quality before marketing | Does not review compounded drugs for safety, effectiveness or quality before they are marketed (FDA, 2026-10-01) |
| Label | A full label reviewed by FDA, with a boxed warning | No label reviewed by FDA for the compounded product |
| Made by | The manufacturer | A 503A pharmacy for an individual prescription, or a 503B outsourcing facility |
| Where adverse events go | Manufacturer and FDA reporting | State-licensed pharmacies that are not outsourcing facilities are not required to submit them to FDA, so reports are likely undercounted |
As of 2026-10-07.
What the labels say
The Zepbound label on DailyMed (effective 2026-08-28) lists two uses: reducing excess body weight and keeping it off in adults with obesity, or with overweight plus at least one weight-related condition; and treat moderate to severe obstructive sleep apnea in adults with obesity. The Mounjaro label (effective 2026-08-27) covers glycemic control in adults and children aged ten and older with type 2 diabetes, and reducing major cardiovascular events in adults with type 2 diabetes at high risk. The Zepbound label says using it with other tirzepatide products or any GLP-1 receptor agonist is "not recommended."
Both labels carry a boxed warning under the heading "WARNING: RISK OF THYROID C-CELL TUMORS." The labels say tirzepatide caused thyroid C-cell tumors in rats and that it is unknown whether it does so in humans. Both are contraindicated for people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. A compounded product has no FDA-reviewed label of its own, so you have to ask the prescriber how these warnings apply.
Manufacturer programs
Manufacturers sell their approved drugs directly. Lilly's LillyDirect page for Zepbound, read 2026-10-07, states that it requires a valid prescription from a licensed provider and lists self-pay prices for the KwikPen starting at $299 a month for the lowest tier and $449 for the highest tiers. Lilly states that the program is not insurance, that higher-tier prices rise if a prescription is not refilled within 45 days, and that terms may change at any time without notice. The same page says LillyDirect works with licensed third-party pharmacies and can connect you with independent virtual care. Prices and terms change, so read the live page.
What FDA says about compounded tirzepatide
- Shortage status. FDA determined the tirzepatide shortage resolved on 2024-10-02, reevaluated it, and issued a new resolved decision on 2024-12-19.
- Enforcement discretion ended. FDA's stated periods ran to 2025-02-18 for 503A pharmacies and 2025-03-19 for outsourcing facilities. A federal court denied a preliminary injunction on 2025-03-05.
- Bulks list. FDA's page, current as of 2026-04-01, says tirzepatide does not appear on the 503B bulks list or on FDA's drug shortage list.
- Proposed exclusion. FDA announced on 2026-04-30 that it proposes to exclude tirzepatide, semaglutide and liraglutide from the 503B bulks list. The Federal Register notice (91 FR 23431) followed on 2026-05-01, and the comment period was extended to 2026-07-30. We found no final action as of 2026-10-07. This is a proposal, not a decision.
- Adverse events. FDA reports "more than 730" adverse event reports for compounded tirzepatide as of 2026-05-31 and says it is not always possible to tell whether the drug caused an event.
- Dosing errors. FDA's GLP-1 page says some reports involve patients prescribed more per dose, more often, or with faster increases than the approved label allows. FDA's earlier alert dated 2024-07-26 was about compounded semaglutide, not tirzepatide; it describes confusion among mL, mg and units on multi-dose vials. We give no dose figures, and neither should a website.
- Fraudulent products. FDA says that "in some cases" the compounding pharmacies named on labels "do not exist."
- Research labels. FDA has warned companies selling tirzepatide and similar products labeled "for research purposes" or "not for human consumption" and urges consumers not to buy them.
The lawful route, step by step
FDA's GLP-1 page states that patients should get a prescription from their doctor and fill it at a state-licensed pharmacy. Its list of telehealth red flags is a useful screen for any online seller:
- Claims of sameness. FDA's list includes the claim that a compounded drug equals an approved one. (FDA, 2026-10-01)
- Prices too good to be true. Deep discounts are on the same list. (FDA, 2026-10-01)
- No prescriber. A service that does not require screening and a prescription by a licensed doctor is on the list. (FDA, 2026-10-01)
- No one to ask. No licensed doctor available to answer questions after you receive the product is a flag. (FDA, 2026-10-01)
- Package problems. Medicine that looks unlike what a local pharmacy gave you, broken packaging, misspelled labels and a wrong pharmacy address all appear on the list. FDA also recommends not using an injectable GLP-1 that arrives warm. (FDA, 2026-10-01)
Our five-point check turns this into questions you can ask any seller. The compounded peptides page explains 503A and 503B in plain words, and semaglutide's page covers the sibling drug.
Whoosh Wellness and tirzepatide
Whoosh states (read 2026-10-07) that it offers compounded tirzepatide as a microdose injection, a full-dose injection and a liposomal tablet, where a licensed physician reviews each online intake and a licensed 503A or 503B US pharmacy fills any prescription. The FDA pages we read address compounded injectables; they do not address the tablet form, so ask about that product specifically. Whoosh also states that completing intake does not guarantee a prescription. Its pages disagree on several points, which we list in the Whoosh Wellness review.
A licensed physician decides whether a prescription is appropriate, so there is no promise of approval.
Questions to ask before you pay
- Brand drug or compounded product? If compounded, which facility made it?
- Can I look up the dispensing pharmacy's license for my own state?
- Whom do I contact with questions once the package arrives, and how?
- Which charges are in writing, which renew on their own, and how does cancelling work?
- Given my own medical history, which boxed-warning risks matter to me?
- Does anything printed on the label say "for research" or "not for human use"?
Sources
- DailyMed: Zepbound label label effective 2026-08-28, read 2026-10-07
- DailyMed: Mounjaro label label effective 2026-08-27, read 2026-10-07
- FDA: Concerns with unapproved GLP-1 drugs page current as of 2026-10-01, read 2026-10-07
- FDA: Policies for compounders as GLP-1 supply stabilizes page current as of 2026-04-01, read 2026-10-07
- FDA: Proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list dated 2026-04-30, read 2026-10-07
- Federal Register: 2026-08552 (proposal) published 2026-05-01, read 2026-10-07
- Federal Register: 2026-12937 (comment period extended) published 2026-06-26, read 2026-10-07
- FDA: Alert on dosing errors with compounded injectable semaglutide products page dated 2024-07-26, read 2026-10-07
- FDA: Warning letters to 30 telehealth companies dated 2026-03-03, read 2026-10-07
- FDA: What to know when promoting compounded drugs page current as of 2026-06-15, read 2026-10-07
- Lilly: LillyDirect Zepbound page as stated by the manufacturer, read 2026-10-07
- Whoosh Wellness: tirzepatide product page as stated by Whoosh, read 2026-10-07
FAQ
Is tirzepatide FDA-approved?
Yes, as the brand drugs Zepbound and Mounjaro, each with a boxed warning about thyroid C-cell tumors. Compounded tirzepatide is not FDA-approved.
Is compounded tirzepatide legal?
FDA said the shortage ended in 2024 and ended its enforcement-discretion periods in early 2025. FDA says a compounded drug might be appropriate if a patient's medical need cannot be met by an approved drug. Compounding is regulated at the state and federal level, so we describe FDA's statements, not a legal opinion.
Did FDA ban compounded tirzepatide?
We did not find that. FDA proposed on 2026-04-30 to exclude tirzepatide from the 503B bulks list, extended the comment period to 2026-07-30 and, as of 2026-10-07, we found no final action.
Can I buy tirzepatide online without a prescription?
Not through the lawful route. FDA has told consumers to avoid tirzepatide products sold under a research or not-for-human-consumption label.
Does Whoosh Wellness offer tirzepatide?
Whoosh states that it offers compounded tirzepatide (read 2026-10-07). Compounded medications are not FDA-approved. A licensed physician decides whether a prescription is appropriate.
How many adverse event reports has FDA received?
FDA reports more than 730 for compounded tirzepatide as of 2026-05-31, and notes pharmacies that are not outsourcing facilities are not required to report, so the true figure may differ.
Not medical advice. See the medical disclaimer.
